BAVA Stock Overview
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
Bavarian Nordic Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.209.80|
|52 Week High||kr.369.30|
|52 Week Low||kr.195.40|
|1 Month Change||-21.13%|
|3 Month Change||-32.43%|
|1 Year Change||-4.29%|
|3 Year Change||39.87%|
|5 Year Change||-23.57%|
|Change since IPO||-17.72%|
Recent News & Updates
Health Check: How Prudently Does Bavarian Nordic (CPH:BAVA) Use Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Calculating The Fair Value Of Bavarian Nordic A/S (CPH:BAVA)
Today we will run through one way of estimating the intrinsic value of Bavarian Nordic A/S ( CPH:BAVA ) by taking the...
|BAVA||DK Biotechs||DK Market|
Return vs Industry: BAVA exceeded the Danish Biotechs industry which returned -14.2% over the past year.
Return vs Market: BAVA underperformed the Danish Market which returned 8.9% over the past year.
|BAVA Average Weekly Movement||6.0%|
|Biotechs Industry Average Movement||6.2%|
|Market Average Movement||5.0%|
|10% most volatile stocks in DK Market||10.1%|
|10% least volatile stocks in DK Market||3.1%|
Stable Share Price: BAVA is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BAVA's weekly volatility (6%) has been stable over the past year.
About the Company
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis
Bavarian Nordic Fundamentals Summary
|BAVA fundamental statistics|
Is BAVA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BAVA income statement (TTM)|
|Cost of Revenue||kr.1.25b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Mar 04, 2022
|Earnings per share (EPS)||-10.48|
|Net Profit Margin||-46.58%|
How did BAVA perform over the long term?See historical performance and comparison
Is Bavarian Nordic undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BAVA (DKK209.8) is trading below our estimate of fair value (DKK400.9)
Significantly Below Fair Value: BAVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BAVA is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: BAVA is unprofitable, so we can't compare its PE Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BAVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BAVA is good value based on its PB Ratio (2.6x) compared to the DK Biotechs industry average (5x).
How is Bavarian Nordic forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BAVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.1%).
Earnings vs Market: BAVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BAVA's is expected to become profitable in the next 3 years.
Revenue vs Market: BAVA's revenue (22.8% per year) is forecast to grow faster than the Danish market (6.5% per year).
High Growth Revenue: BAVA's revenue (22.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BAVA's Return on Equity is forecast to be low in 3 years time (3.4%).
How has Bavarian Nordic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BAVA is currently unprofitable.
Growing Profit Margin: BAVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BAVA is unprofitable, and losses have increased over the past 5 years at a rate of 21.9% per year.
Accelerating Growth: Unable to compare BAVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BAVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).
Return on Equity
High ROE: BAVA has a negative Return on Equity (-12.78%), as it is currently unprofitable.
How is Bavarian Nordic's financial position?
Financial Position Analysis
Short Term Liabilities: BAVA's short term assets (DKK3.6B) exceed its short term liabilities (DKK2.3B).
Long Term Liabilities: BAVA's short term assets (DKK3.6B) exceed its long term liabilities (DKK2.0B).
Debt to Equity History and Analysis
Debt Level: BAVA has more cash than its total debt.
Reducing Debt: BAVA's debt to equity ratio has increased from 1.7% to 15% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BAVA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BAVA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Bavarian Nordic current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BAVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BAVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BAVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BAVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BAVA's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Chaplin (54 yo)
Dr. Paul John Chaplin, M.Sc., Ph D., has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S f...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Paul's total compensation is reasonable compared to companies of similar size in the Danish market.
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Experienced Management: BAVA's management team is considered experienced (2.6 years average tenure).
Experienced Board: BAVA's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.5%.
Bavarian Nordic A/S's employee growth, exchange listings and data sources
- Name: Bavarian Nordic A/S
- Ticker: BAVA
- Exchange: CPSE
- Founded: 1992
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.14.755b
- Shares outstanding: 70.33m
- Website: https://www.bavarian-nordic.com
Number of Employees
- Bavarian Nordic A/S
- Philip Heymans Alle 3
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 21:20|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.